DSM Capital Partners’s Novo Nordisk NVO Stock Holding History

DSM Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,760,978	Closed	-$122M	–	47
2025 Q2	$122M	Sell	1,760,978 -295,609	-14%	-$20.1M	1.8%	18
2025 Q1	$143M	Buy	2,056,587 +49,175	+2%	+$4.06M	2.5%	12
2024 Q4	$173M	Buy	2,007,412 +286,912	+17%	+$31M	2.67%	11
2024 Q3	$205M	Buy	1,720,500 +126,579	+8%	+$16.9M	3.13%	10
2024 Q2	$228M	Buy	1,593,921 +1,593,303	+257,816%	+$211M	3.3%	9
2024 Q1	$79.4K	Buy	618 +166	+37%	+$19.8K	﹤0.01%	58
2023 Q4	$46.8K	Buy	+452	New	+$44.7K	﹤0.01%	66
2016 Q1	–	Sell	-2,980	Closed	-$87K	–	41
2015 Q4	$87K	Hold	2,980	–	–	﹤0.01%	39
2015 Q3	$81K	Hold	2,980	–	–	﹤0.01%	39
2015 Q2	$82K	Sell	2,980 -970	-25%	-$27.3K	﹤0.01%	40
2015 Q1	$105K	Hold	3,950	–	–	﹤0.01%	38
2014 Q4	$84K	Hold	3,950	–	–	﹤0.01%	43
2014 Q3	$94K	Hold	3,950	–	–	﹤0.01%	75
2014 Q2	$91K	Buy	+3,950	New	+$87.2K	﹤0.01%	76

Other funds holding NVO

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DSM Capital Partners's NVO Position: Q3 2025 in Review

DSM Capital Partners sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 1,760,978 shares — an estimated $122M sold.

DSM Capital Partners first reported a position in NVO in Q2 2014 and held it in 14 quarters. The position peaked at $228M in Q2 2024. 1,398 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

DSM Capital Partners reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
DSM Capital Partners sold 1,760,978 Novo Nordisk shares in Q3 2025, an estimated $122M.
DSM Capital Partners first reported a position in Novo Nordisk in Q2 2014 and held it in 14 quarters.
DSM Capital Partners's Novo Nordisk position peaked at $228M in Q2 2024.
1,398 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on DSM Capital Partners's 13F filing for Q3 2025, filed 22 Oct 2025.